NCT06766305View on ClinicalTrials.gov

QL1706 Combined With SOX Used in Theperioperative Treatment

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

June 30, 2031

Conditions
Gastric CancersEsophagogastric Junction Cancers
Interventions
DRUG

QL1706 combined with SOX

QL1706 + SOX (3 cycles) before surgery → radical surgery (D2) → QL1706 + SOX (5 cycles) after surgery → QL1706 monotherapy maintenance （up to 1 year before and after surgery); Phase 1 (initial dose cohort) ： QL1706 5mg/kg ；Phase 1 (dose escalation cohort)：QL1706 7.5mg/kg ；Phase 2：QL1706 RP2D

Trial Locations (1)

310000

RECRUITING

Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou

All Listed Sponsors
lead

Xiangdong Cheng

OTHER